Novo Holdings A/S’s Aligos Therapeutics ALGS Stock Holding History

Novo Holdings A/S’s Portfolio ALGS Stock Details ALGS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-78,000	Closed	-$2.15M	–	49
2022 Q3	$2.15M	Hold	78,000	–	–	0.1%	51
2022 Q2	$2.36M	Hold	78,000	–	–	0.12%	53
2022 Q1	$4.19M	Sell	78,000 -26,583	-25%	-$2.13M	0.22%	46
2021 Q4	$31M	Hold	104,583	–	–	1.47%	13
2021 Q3	$40.6M	Hold	104,583	–	–	2.1%	12
2021 Q2	$53.3M	Hold	104,583	–	–	2.36%	11
2021 Q1	$59.5M	Hold	104,583	–	–	2.46%	13
2020 Q4	$72.3M	Buy	+104,583	New	+$50.9M	3.1%	12

Other funds holding ALGS

EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return

VVM

Versant Venture Management San Francisco, California $163M AUM 240.43% 1-Year Est. Return

HHLR Advisors Grand Cayman, Cayman Islands $832M AUM 32.38% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Newtyn Management New York $801M AUM 23.14% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Novo Holdings A/S's ALGS Position: Q4 2022 in Review

Novo Holdings A/S sold out of Aligos Therapeutics (ALGS) in Q4 2022, closing a stake of 78,000 shares — an estimated $2.15M sold.

Novo Holdings A/S first reported a position in ALGS in Q4 2020 and held it in 8 quarters. The position peaked at $72.3M in Q4 2020. 38 funds tracked by Wall St. Rank hold ALGS as of Q4 2022.

Novo Holdings A/S reported no remaining Aligos Therapeutics position as of Q4 2022 after selling out during the quarter.
Novo Holdings A/S sold 78,000 Aligos Therapeutics shares in Q4 2022, an estimated $2.15M.
Novo Holdings A/S first reported a position in Aligos Therapeutics in Q4 2020 and held it in 8 quarters.
Novo Holdings A/S's Aligos Therapeutics position peaked at $72.3M in Q4 2020.
38 funds tracked by Wall St. Rank held Aligos Therapeutics as of Q4 2022.

Based on Novo Holdings A/S's 13F filing for Q4 2022, filed 14 Feb 2023.